Shattuck Labs (NASDAQ:STTK) Announces Quarterly Earnings Results

Shattuck Labs (NASDAQ:STTK) posted its earnings results on Thursday. The company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12), FiscalAI reports. The company had revenue of ($1.00) million during the quarter, compared to the consensus estimate of $0.17 million.

Shattuck Labs Trading Up 17.5%

Shares of STTK opened at $5.99 on Friday. The stock’s 50-day moving average price is $4.17 and its two-hundred day moving average price is $2.83. Shattuck Labs has a 12 month low of $0.69 and a 12 month high of $6.00. The company has a market capitalization of $379.05 million, a PE ratio of -7.78 and a beta of 1.55.

Key Shattuck Labs News

Here are the key news stories impacting Shattuck Labs this week:

• Positive Sentiment: Needham initiated coverage with a “Buy” and a $25.00 price target, a materially higher target that signals strong upside and likely attracted buying interest. Needham Initiation
• Positive Sentiment: Wedbush raised its price target from $4.00 to $8.00 and kept an “Outperform” rating, providing additional analyst support and a nearer-term beat-the-street catalyst. Wedbush Target Raise
• Negative Sentiment: HC Wainwright cut its FY2026–FY2028 EPS forecasts (FY2026 to ($0.83) from ($0.71); FY2027 to ($0.88) from ($0.76); FY2028 to ($1.04) from ($0.90)) while still maintaining a “Buy” rating and a $6 price target — the revisions signal slower expected progress in profitability and could pressure longer-term expectations. HC Wainwright Note
• Negative Sentiment: Shattuck’s published Q4/FY2025 results showed EPS roughly in line with estimates but revenue missed expectations (company reported negative/weak revenue for the quarter vs. consensus), a mixed report that limits upside from fundamentals until revenue trends improve. Q4 & FY2025 Results

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on STTK. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd. HC Wainwright upgraded shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a research report on Monday, December 1st. Wedbush boosted their target price on shares of Shattuck Labs from $4.00 to $8.00 and gave the stock an “outperform” rating in a research note on Friday. TD Cowen reiterated a “buy” rating on shares of Shattuck Labs in a research note on Friday. Finally, Piper Sandler began coverage on Shattuck Labs in a report on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price objective on the stock. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Shattuck Labs has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Hedge Funds Weigh In On Shattuck Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in STTK. Turtle Creek Wealth Advisors LLC acquired a new stake in Shattuck Labs during the 3rd quarter valued at approximately $29,000. Virtu Financial LLC bought a new stake in shares of Shattuck Labs in the 3rd quarter valued at $38,000. AQR Capital Management LLC increased its position in shares of Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after buying an additional 31,355 shares during the period. Qube Research & Technologies Ltd bought a new position in Shattuck Labs during the second quarter worth $44,000. Finally, Squarepoint Ops LLC acquired a new position in Shattuck Labs in the third quarter valued at $46,000. 58.74% of the stock is owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.